NDA 211801 · Ardelyx INC
Ibsrela
Tenapanor Hydrochloride · Oral
NovelLast checked: Nov 19, 2026Latest source record: May 20, 2025 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations
First approved
2019
Sep 12, 2019
Approved uses
1
Original approval plus efficacy supplements
Registered trials
38
15 Phase 3, 2 recruiting
FAERS reports
3,714
1,104 serious, 114 with death reported
AI brief across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.
Boxed warning
WARNING: RISK OF SERIOUS DEHYDRATION IN PEDIATRIC PATIENTS IBSRELA is contraindicated in patients less than 6 years of age; in nonclinical studies in young juvenile rats administration of tenapanor caused deaths presumed to be due to dehydration [see Contraindications (4) , Use in Specific Populations (8.4) ]. Avoid use of IBSRELA in patients 6 years to less than 12 years of age [see Warnings and Precautions (5.1) , Use in Specific Populations (8.4) ]. The safety and effectiveness of IBSRELA have not been established in patients less than 18 years of age [see Use in Specific Populations (8.4) ] . WARNING: RISK OF SERIOUS DEHYDRATION IN PEDIATRIC PATIENTS See full prescribing information for complete boxed warning. IBSRELA is contraindicated in patients less than 6 years of age; in young juvenile rats, tenapanor caused death presumed to be due to dehydration. ( 4 , 8.4 ) Avoid use of...
What it is approved for
From the label in effect May 28, 2025.
IBSRELA is indicated for treatment of irritable bowel syndrome with constipation (IBS-C) in adults. IBSRELA is a sodium/hydrogen exchanger 3 (NHE3) inhibitor indicated for treatment of irritable bowel syndrome with constipation (IBS-C) in adults. ( 1 )
Mechanism: Tenapanor is a locally acting inhibitor of the sodium/hydrogen exchanger 3 (NHE3), an antiporter expressed on the apical surface of the small intestine and colon primarily responsible for the absorption of dietary sodium. In vitro and animal studies indicate its major metabolite, M1, is not active against NHE3. By inhibiting NHE3 on the apical surface of the enterocytes, tenapanor reduces absorption of sodium from the small intestine and colon, resulting in an increase in water secretion into the intestinal lumen, which accelerates intestinal transit time and results in a softer stool...
Approval history
Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.
1 products under this application
- IBSRELA · TENAPANOR HYDROCHLORIDE EQ 50MG BASE · TABLET, ORAL · Prescription
Clinical trials
Interventional ClinicalTrials.gov studies with "Tenapanor" as an intervention, any sponsor and status, largest first.
- A Phase 3 Study of Tenapanor to Treat Hyperphosphatemia in ESRD Patients on DialysisPivotal-lookingCompleted
ArdelyxIndustry
NCT03427125 · 1,559 participants · Start Jan 8, 2018 · Primary completion Nov 15, 2019
Drug: Tenapanor; Placebo and 1 more · For: Hyperphosphatemia
Sites: The Bronx, New York; Winston-Salem, North Carolina
- A 26-Wk Study to Assess Safety & Efficacy of Tenapanor for T/t of Chronic Idiopathic Constipation in AdultsPivotal-lookingRecruiting
ArdelyxIndustry
NCT07382167 · 692 participants (planned) · Start Jan 13, 2026 · Primary completion Feb 26, 2027
Drug: Tenapanor 5 mg BID; Tenapanor 25 mg BID and 2 more · For: Chronic Idiopathic Constipation (CIC)
Sites: Foley, Alabama; Saraland, Alabama; Chandler, Arizona · 109 sites in all
- A 12-Week Study With a 4-Week Randomized Withdrawal Period to Evaluate the Efficacy and Safety of Tenapanor for the Treatment of IBS-CPivotal-lookingCompleted
ArdelyxIndustry
NCT02621892 · 606 participants · Start Oct 2015 · Primary completion Mar 2017
Drug: Tenapanor; Placebo · For: Constipation Predominant Irritable Bowel Syndrome
Sites: Birmingham, Alabama; Huntsville, Alabama; Chandler, Arizona · 111 sites in all
- A 26-Week Study to Evaluate the Efficacy and Safety of Tenapanor in IBS-CPivotal-lookingCompleted
ArdelyxIndustry
NCT02686138 · 593 participants · Start Dec 2015 · Primary completion Aug 2017
Drug: Tenapanor; Placebo · For: Constipation Predominant Irritable Bowel Syndrome
Sites: Dothan, Alabama; Foley, Alabama; Huntsville, Alabama · 117 sites in all
- The Efficacy of AZD1722 in Constipation Predominant Irritable Bowel Syndrome (IBS-C)Pivotal-lookingCompleted
ArdelyxIndustry
NCT01923428 · 356 participants · Start Aug 2013 · Primary completion Oct 2014
Drug: AZD1722; Placebo · For: Constipation Predominant Irritable Bowel Syndrome
Sites: Boulder, Colorado; Greensboro, North Carolina; Winston-Salem, North Carolina · 4 sites in all
- Study to Evaluate the Use of Tenapanor as Core Therapy in the Treatment of HyperphosphatemiaPivotal-lookingCompleted
ArdelyxIndustry
NCT04549597 · 333 participants · Start Nov 20, 2020 · Primary completion Oct 13, 2021
Drug: Tenapanor · For: Chronic Kidney Disease Requiring Chronic Dialysis; Hyperphosphatemia
Sites: Lauderdale Lakes, Florida
- A Long-Term Safety Study of Tenapanor for the Treatment of IBS-CPivotal-lookingCompleted
ArdelyxIndustry
NCT02727751 · 312 participants · Start Mar 2016 · Primary completion Oct 2017
Drug: Tenapanor · For: Constipation Predominant Irritable Bowel Syndrome
Sites: Miami, Florida
- Study to Evaluate the Efficacy of Tenapanor as Adjunctive Therapy to Phosphate Binder TherapyPivotal-lookingCompleted
ArdelyxIndustry
NCT03824587 · 236 participants · Start Feb 28, 2019 · Primary completion Jul 17, 2019
Drug: Tenapanor; Placebo and 1 more · For: Hyperphosphatemia
Sites: Huntsville, Alabama; Pine Bluff, Arkansas; Beverly Hills, California · 48 sites in all
Most reported adverse reactions
FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.
- diarrhoea1,288
- product use issue444
- inappropriate schedule of product administration401
- therapy interrupted294
- product use in unapproved indication261
- abdominal distension247
- drug ineffective219
- off label use209
- insurance issue208
- intentional underdose179
- abdominal pain upper167
- abdominal pain148
FAERS reports by year
By the date FDA received the report.
View as table
| Year | Reports |
|---|---|
| 2016 | 1 |
| 2017 | 1 |
| 2019 | 2 |
| 2020 | 2 |
| 2021 | 1 |
| 2022 | 42 |
| 2023 | 103 |
| 2024 | 353 |
| 2025 | 500 |
| 2026 | 2,709 |
Recalls
0 FDA enforcement reports for this application.
No recalls on record for this application.
Shortages
FDA's drug shortage list.
Not on FDA's shortage list.
Medicare spending
CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.
Part D: Ibsrela (Tenapanor HCl)
2024 spending
$68.4M
Beneficiaries
9,699
32,759 claims
Per beneficiary
$7,056
$29.05 per unit
View as table
| Year | Spending |
|---|---|
| 2020 | $0 |
| 2021 | $0 |
| 2022 | $5,485,812 |
| 2023 | $33,839,561 |
| 2024 | $68,440,705 |
Published evidence
PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.
- Tenapanor as Therapy for Hyperphosphatemia in Maintenance Dialysis Patients: Results from the OPTIMIZE Study.
Sprague SM, Weiner DE, Tietjen DP, et al. · Kidney360 2024 · Randomized Controlled Trial, Research Support, Non-U.S. Gov't
- Efficacy of drugs in chronic idiopathic constipation: a systematic review and network meta-analysis.
Luthra P, Camilleri M, Burr NE, et al. · Lancet Gastroenterol Hepatol 2019 · Research Support, N.I.H., Extramural, Systematic Review
- Tenapanor: A new treatment option for hyperphosphatemia in end stage kidney disease.
Lin T, Al-Makki A, Shepler B · J Pharm Pharm Sci 2022 · Systematic Review
- Effects of Tenapanor on Cytochrome P450-Mediated Drug-Drug Interactions.
Johansson S, Rosenbaum DP, Ahlqvist M, et al. · Clin Pharmacol Drug Dev 2017 · Clinical Trial, Phase I
- Efficacy and safety of tenapanor in hemodialysis patients with hyperphosphatemia: A systematic review and meta-analysis of randomized placebo-controlled trials.
Luo H, Feng J, Zhang Y, et al. · Ther Apher Dial 2023 · Meta-Analysis, Systematic Review
- Tenapanor Improves Abdominal Symptoms Irrespective of Changes in Complete Spontaneous Bowel Movement Frequency in Adults with Irritable Bowel Syndrome with Constipation.
Brenner DM, Sayuk GS, Cash BD, et al. · Dig Dis 2025 · Clinical Trial, Phase II, Clinical Trial, Phase III
Sponsor: Ardelyx INC
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.